tirzepatide surpass trials SURPASS-CVOT trial results: Tirzepatide's impact on diabetes and cardiovascular disease | Paramesh Shamanna posted on the topic surpass-cvot tirzepatide Efficacy and safety

doi: 10.1007/s40261-016-0462-3 6 ViriliCAntonelliASantaguidaMGBenvengaSCentanniM

doi: 10.1016/bs.ai.2017.06.004 146 NissilEKorpelaKLokkiAIPaakkanenRJokirantaSde VosWMet al

Daily Protein Targets by Goal Muscle Preservation (Cutting Focus) 0.8-1.0 grams per pound of body weight Example: 180 lb individual = 145-180g protein daily Muscle Building (Recomp/Lean Bulk) 1.0-1.2 grams per pound of body weight Example: 180 lb individual = 180-215g protein daily Distributing protein across 5-6 smaller meals rather than 2-3 large ones becomes particularly important with Retatrutide

Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials